Abstract
Background: Our objectives were to assess the timing of testing, the types of diagnostic assays used, and the costs associated with the diagnosis of HIV-1 infection among infants born to HIV-1-infected women enrolled in the International Maternal Pediatric Adolescent AIDS Clinical Trials Group Protocol 1025 (P1025). Methods: P1025 is a prospective cohort study of HIV-1-infected women and their infants at clinical sites in the United States and Puerto Rico. Enrollment began in 2002 and is ongoing. Follow-up of infants continued for at least 6 months after delivery/birth. The study population for this analysis comprised all live born infants of known HIV-1 infection status, born by December 31, 2006 to enrolled women. Results: Nine hundred eighty-eight infants had 5147 HIV-1 diagnostic test results reported. The median number of HIV-1 diagnostic assays performed per infant was 5 (10th, 90th percentiles: 3, 7), and the greatest number of tests reported per infant was 13. The median ages at the time of the first, second, third, and fourth HIV-1 diagnostic assay were 0.1, 2.3, 7.0, and 17.6 weeks, respectively. Nucleic acid amplification tests (NAATs) represented 86.9% of all diagnostic assays (HIV-1 DNA PCR assays: n = 4082 79.3%; other NAATs: n = 389 7.6%). The median cost per infant for HIV-1 diagnostic testing was $1168 (10th, 90th percentiles: $762, $1642). Conclusions: Most assays reported for HIV-1-exposed infants at clinical sites in the United States and Puerto Rico were NAATs, but the number of HIV-1 diagnostic assays performed per infant, and the cost associated with HIV-1 diagnostic testing per infant, varied greatly.
| Original language | English |
|---|---|
| Pages (from-to) | 614-618 |
| Number of pages | 5 |
| Journal | Pediatric Infectious Disease Journal |
| Volume | 28 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 1 2009 |
Fingerprint
Keywords
- Diagnostic testing
- HIV
- Infants
- North America
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Infectious Diseases
- Microbiology (medical)
- Medicine(all)
Cite this
Human immunodeficiency virus diagnostic testing of infants at clinical sites in North America 2002-2006. / Read, Jennifer S.; Brogly, Susan; Basar, Michael; Scott, Gwendolyn B.
In: Pediatric Infectious Disease Journal, Vol. 28, No. 7, 01.07.2009, p. 614-618.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Human immunodeficiency virus diagnostic testing of infants at clinical sites in North America 2002-2006
AU - Read, Jennifer S.
AU - Brogly, Susan
AU - Basar, Michael
AU - Scott, Gwendolyn B
PY - 2009/7/1
Y1 - 2009/7/1
N2 - Background: Our objectives were to assess the timing of testing, the types of diagnostic assays used, and the costs associated with the diagnosis of HIV-1 infection among infants born to HIV-1-infected women enrolled in the International Maternal Pediatric Adolescent AIDS Clinical Trials Group Protocol 1025 (P1025). Methods: P1025 is a prospective cohort study of HIV-1-infected women and their infants at clinical sites in the United States and Puerto Rico. Enrollment began in 2002 and is ongoing. Follow-up of infants continued for at least 6 months after delivery/birth. The study population for this analysis comprised all live born infants of known HIV-1 infection status, born by December 31, 2006 to enrolled women. Results: Nine hundred eighty-eight infants had 5147 HIV-1 diagnostic test results reported. The median number of HIV-1 diagnostic assays performed per infant was 5 (10th, 90th percentiles: 3, 7), and the greatest number of tests reported per infant was 13. The median ages at the time of the first, second, third, and fourth HIV-1 diagnostic assay were 0.1, 2.3, 7.0, and 17.6 weeks, respectively. Nucleic acid amplification tests (NAATs) represented 86.9% of all diagnostic assays (HIV-1 DNA PCR assays: n = 4082 79.3%; other NAATs: n = 389 7.6%). The median cost per infant for HIV-1 diagnostic testing was $1168 (10th, 90th percentiles: $762, $1642). Conclusions: Most assays reported for HIV-1-exposed infants at clinical sites in the United States and Puerto Rico were NAATs, but the number of HIV-1 diagnostic assays performed per infant, and the cost associated with HIV-1 diagnostic testing per infant, varied greatly.
AB - Background: Our objectives were to assess the timing of testing, the types of diagnostic assays used, and the costs associated with the diagnosis of HIV-1 infection among infants born to HIV-1-infected women enrolled in the International Maternal Pediatric Adolescent AIDS Clinical Trials Group Protocol 1025 (P1025). Methods: P1025 is a prospective cohort study of HIV-1-infected women and their infants at clinical sites in the United States and Puerto Rico. Enrollment began in 2002 and is ongoing. Follow-up of infants continued for at least 6 months after delivery/birth. The study population for this analysis comprised all live born infants of known HIV-1 infection status, born by December 31, 2006 to enrolled women. Results: Nine hundred eighty-eight infants had 5147 HIV-1 diagnostic test results reported. The median number of HIV-1 diagnostic assays performed per infant was 5 (10th, 90th percentiles: 3, 7), and the greatest number of tests reported per infant was 13. The median ages at the time of the first, second, third, and fourth HIV-1 diagnostic assay were 0.1, 2.3, 7.0, and 17.6 weeks, respectively. Nucleic acid amplification tests (NAATs) represented 86.9% of all diagnostic assays (HIV-1 DNA PCR assays: n = 4082 79.3%; other NAATs: n = 389 7.6%). The median cost per infant for HIV-1 diagnostic testing was $1168 (10th, 90th percentiles: $762, $1642). Conclusions: Most assays reported for HIV-1-exposed infants at clinical sites in the United States and Puerto Rico were NAATs, but the number of HIV-1 diagnostic assays performed per infant, and the cost associated with HIV-1 diagnostic testing per infant, varied greatly.
KW - Diagnostic testing
KW - HIV
KW - Infants
KW - North America
UR - http://www.scopus.com/inward/record.url?scp=77449136377&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77449136377&partnerID=8YFLogxK
U2 - 10.1097/INF.0b013e31819ac33b
DO - 10.1097/INF.0b013e31819ac33b
M3 - Article
C2 - 19478686
AN - SCOPUS:77449136377
VL - 28
SP - 614
EP - 618
JO - Pediatric Infectious Disease Journal
JF - Pediatric Infectious Disease Journal
SN - 0891-3668
IS - 7
ER -